Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments

  1. Zan He
  2. Zijuan Xin
  3. Qiong Yang
  4. Chen Wang
  5. Meng Li
  6. Wei Rao
  7. Zhimin Du
  8. Jia Bai
  9. Zixuan Guo
  10. Xiuyan Ruan
  11. Zhaojun Zhang
  12. Xiangdong Fang  Is a corresponding author
  13. Hua Zhao  Is a corresponding author
  1. General Hospital of People's Liberation Army, China
  2. Chinese Academy of Sciences, China

Abstract

Acral melanoma (AM) exhibits a high incidence in Asian patients with melanoma, and it is not well treated with immunotherapy. However, little attention has been paid to the characteristics of the immune microenvironment in AM. Therefore, in this study, we collected clinical samples from Chinese patients with AM and conducted single-cell RNA sequencing to analyze the heterogeneity of its tumour microenvironments (TMEs) and the molecular regulatory network . Our analysis revealed that genes, such as TWIST1, EREG, TNFRSF9, and CTGF could drive the deregulation of various TME components. The molecular interaction relationships between TME cells, such as MIF-CD44 and TNFSF9-TNFRSF9, might be an attractive target for developing novel immunotherapeutic agents.

Data availability

Sequencing data have been deposited in GSA under accession codes HRA001804.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Zan He

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Zijuan Xin

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Qiong Yang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Chen Wang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Meng Li

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Wei Rao

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Zhimin Du

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Jia Bai

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Zixuan Guo

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Xiuyan Ruan

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Zhaojun Zhang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Xiangdong Fang

    Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    For correspondence
    fangxd@big.ac.cn
    Competing interests
    The authors declare that no competing interests exist.
  13. Hua Zhao

    Department of Dermatology, General Hospital of People's Liberation Army, Beijing, China
    For correspondence
    hualuck301@163.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7139-1844

Funding

National Natural Science Foundation of China (81672698)

  • Hua Zhao

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. C Daniela Robles-Espinoza, International Laboratory for Human Genome Research, Mexico

Ethics

Human subjects: All samples were obtained from the General Hospital of the People's Liberation Army, Beijing, China. All volunteers signed informed consent prior to sample acquisition. Four primary AM tissues, three paracancerous tissues, and a metastatic lymph gland sample were included in this cohort. This study was approved by the Ethics Committee of Chinese PLA General Hospital and complied with all relevant ethical regulations(Approval No. S2021-626).

Version history

  1. Preprint posted: August 28, 2021 (view preprint)
  2. Received: March 14, 2022
  3. Accepted: July 25, 2022
  4. Accepted Manuscript published: July 27, 2022 (version 1)
  5. Version of Record published: August 23, 2022 (version 2)
  6. Version of Record updated: September 1, 2022 (version 3)

Copyright

© 2022, He et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,822
    views
  • 400
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zan He
  2. Zijuan Xin
  3. Qiong Yang
  4. Chen Wang
  5. Meng Li
  6. Wei Rao
  7. Zhimin Du
  8. Jia Bai
  9. Zixuan Guo
  10. Xiuyan Ruan
  11. Zhaojun Zhang
  12. Xiangdong Fang
  13. Hua Zhao
(2022)
Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments
eLife 11:e78616.
https://doi.org/10.7554/eLife.78616

Share this article

https://doi.org/10.7554/eLife.78616

Further reading

    1. Cancer Biology
    2. Cell Biology
    Linda Zhang, Joanne I Hsu ... Margaret A Goodell
    Research Article

    The DNA damage response is critical for maintaining genome integrity and is commonly disrupted in the development of cancer. PPM1D (protein phosphatase Mg2+/Mn2+-dependent 1D) is a master negative regulator of the response; gain-of-function mutations and amplifications of PPM1D are found across several human cancers making it a relevant pharmacological target. Here, we used CRISPR/Cas9 screening to identify synthetic-lethal dependencies of PPM1D, uncovering superoxide dismutase-1 (SOD1) as a potential target for PPM1D-mutant cells. We revealed a dysregulated redox landscape characterized by elevated levels of reactive oxygen species and a compromised response to oxidative stress in PPM1D-mutant cells. Altogether, our results demonstrate a role for SOD1 in the survival of PPM1D-mutant leukemia cells and highlight a new potential therapeutic strategy against PPM1D-mutant cancers.

    1. Cancer Biology
    Haley R Noonan, Alexandra M Thornock ... Leonard I Zon
    Research Article

    Developmental signaling pathways associated with growth factors such as TGFb are commonly dysregulated in melanoma. Here we identified a human TGFb enhancer specifically activated in melanoma cells treated with TGFB1 ligand. We generated stable transgenic zebrafish with this TGFb Induced Enhancer driving green fluorescent protein (TIE:EGFP). TIE:EGFP was not expressed in normal melanocytes or early melanomas but was expressed in spatially distinct regions of advanced melanomas. Single-cell RNA-sequencing revealed that TIE:EGFP+ melanoma cells down-regulated interferon response while up-regulating a novel set of chronic TGFb target genes. ChIP-sequencing demonstrated that AP-1 factor binding is required for activation of chronic TGFb response. Overexpression of SATB2, a chromatin remodeler associated with tumor spreading, showed activation of TGFb signaling in early melanomas. Confocal imaging and flow cytometric analysis showed that macrophages localize to TIE:EGFP+ regions and preferentially phagocytose TIE:EGFP+ melanoma cells compared to TIE:EGFP- melanoma cells. This work identifies a TGFb induced immune response and demonstrates the need for the development of chronic TGFb biomarkers to predict patient response to TGFb inhibitors.